Olema Pharmaceuticals (OLMA) Non-Current Debt (2025 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Non-Current Debt of $3.0 million for Q1 2026, little changed quarter-over-quarter from $3.0 million in Q4 2025.
Powered by 
Analysis
Olema Pharmaceuticals (OLMA) Non-Current Debt (2025 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Non-Current Debt for 2 consecutive years, with $3.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt changed N/A year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $3.0 million (changed N/A YoY), while the FY2025 annual figure was $3.0 million, changed N/A from the prior year.
- Non-Current Debt steadied at $3.0 million in Q1 2026 per OLMA's latest filing, from $3.0 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $3.0 million in Q2 2025 and bottomed at $3.0 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 882.16 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 8.96 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Olema Pharmaceuticals | 1.13 Bn | 1.13 Bn | - | 3.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.00 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Dec 31, 2025 | 3.00 Mn |
| Sep 30, 2025 | 3.00 Mn |
| Jun 30, 2025 | 3.00 Mn |